Delving into the Latest Updates on Auron Healthcare GmbH with Synapse

概览

关联

1

项与 Auron Healthcare GmbH 相关的药物

AMT-2003

靶点-

作用机制

免疫刺激剂

在研机构-

原研机构

Auron Healthcare GmbH

在研适应症-

非在研适应症

晚期癌症 [+8]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

3

项与 Auron Healthcare GmbH 相关的临床试验

NCT00405873

/ Terminated临床2期

A Prospective, Open, Single-arm, Multicenter Phase II Clinical Trial to Evaluate the Tumour Response and Safety in Patients With Advanced Primary Hepatocellular Carcinoma Treated With AMT2003

The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced primary hepatocellular carcinoma
The primary endpoint is best overall response rate within 20 weeks after registration

开始日期2007-03-01

申办/合作机构

Auron Healthcare GmbH

NCT00405561

/ Terminated临床2/3期

A Prospective, Open, Single-Arm, Multicenter Phase II Clinical Trial to Evaluate the Progression Free Survival and Safety in Patients With Advanced Colorectal Carcinoma Treated With AMT2003

The purpose of the study is to evaluate efficacy and safety of AMT2003 in cancer patients with advanced colorectal carcinoma.
The primary endpoint is progression free survival rate at 18 weeks after registration

开始日期2006-10-01

申办/合作机构

Auron Healthcare GmbH

NCT00332280

/ Terminated临床2/3期

A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo

The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease.
The primary evaluation criterion is clinical benefit response.

开始日期2006-05-01

申办/合作机构

Auron Healthcare GmbH

100 项与 Auron Healthcare GmbH 相关的临床结果

登录后查看更多信息

0 项与 Auron Healthcare GmbH 相关的专利（医药）

登录后查看更多信息

1

项与 Auron Healthcare GmbH 相关的文献（医药）

2009-04-02·International Journal of Oncology2区 · 医学

AMT: Preclinical pharmacology studies

2区 · 医学

Article

作者: Scheele, Juergen ; Drevs, Joachim ; Dorn, Annette ; Bruyns, Eddy ; Niazi, Faiz ; Fiebig, Heinz Herbert ; Maier, Armin ; Diergarten, Klaus

Auron-Misheil-Therapy (AMT) consisting of aqueous camomile extract supplemented with calcium, vitamins, the antihistamine chlorpheniramine and human insulin is under development as anti-cancer treatment. AMT was preclinically investigated in tumour cell lines and tumour xenografts to guide clinical phase I/II studies. AMT was tested against 56 human tumour cell lines, in a clonogenic assay in 98 patient-derived xenografts and in in vivo studies. AMT showed in vitro cytotoxic activity with highest susceptibility in cervical cancer, glioblastoma and colon cancers. In the clonogenic assay, anti- cancer activity of AMT was most active in cervical and uterine tumours, in colon cancer, glioblastoma, leukaemia, melanoma and pancreatic cancer. In vivo, AMT showed slight activity in tumour xenograft models of colon and mammary cancer. It also showed immune stimulatory effects by induction of IL-6- and TNF-alpha secretion in human PBMCs. The immune stimulatory potential of AMT, together with slight anti-tumour efficacy observed in the present study, indicates a role of AMT in tumour therapy.

100 项与 Auron Healthcare GmbH 相关的药物交易

登录后查看更多信息

100 项与 Auron Healthcare GmbH 相关的转化医学

登录后查看更多信息